Fosmanogepix

Pfizer has acquired Amplyx Pharmaceuticals, gaining rights to fosmanogepix, a novel Phase 2 antifungal compound that could address drug-resistant fungal infections with mortality rates of 30-80%.

Westmead Hospital launches groundbreaking clinical trials for Fosmanogepix, a new class of antifungal drug designed to combat drug-resistant invasive fungal infections.

Cresemba's market presence expanded to over 70 countries, achieving USD 533 million in global sales, marking a 20% year-over-year growth and solidifying its position as a leading antifungal.

Basilea Pharmaceutica has initiated a Phase 3 trial (FAST-IC) to assess fosmanogepix for treating candidemia and invasive candidiasis in adults.